ClinicalTrials.gg
CompletedNCT07304843Updated Oct 16, 2026

A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

A Phase 1/2 interventional study of golexanolone and golexanolone in Primary Biliary Cholangitis (PBC), sponsored by Umecrine Cognition AB. Completed at 38 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Umecrine Cognition AB · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Apr 2023, registered Nov 2025).
Updated Oct 16, 2026Now CompletedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Liver Cirrhosis, Biliary with a site in Spain — 7 open to participants now, 12 under way, 4 of them phase 3. Liver Cirrhosis, Biliary · Spain.

Enrollment
9th of 26
207 · median 129
Started
2023
with 3 others
Phase 1/2
Only one
of the 32
Registered
31st of 32
by date

Among the 32 studies in Liver Cirrhosis, Biliary with a site in Spain, this one is the 9th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2023, is the only one in phase 1/2, and was the 31st registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

7 of the 32 studies in Liver Cirrhosis, Biliary with a site in Spain are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Liver Cirrhosis, Biliary with a site in Spain, or all of them as a file.
02

Study summary

The present phase 1b/2 randomised, double-blind, placebo-controlled, two-part study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of two dose levels of golexanolone compared with placebo among subjects with a history of non-cirrhotic or Child-Pugh class A cirrhotic Primary Biliary Cholangitis (PBC) with clinically significant fatigue and cognitive symptoms on stable background standard of care (SoC) PBC medication. The objectives of this research study are to assess the safety and tolerability as well the pharmacokinetic (PK) characteristics of golexanolone administered 40 mg BID for 5 days in the target population (part A) and to assess the safety and tolerability, the effects of golexanolone on health-related quality of life (HRQoL), including fatigue, day-time sleepiness and cognitive function as well as Investigator's overall impression of treatment effect of 28 days twice per day (BID) treatment with two dose levels of golexanolone versus placebo (part B).

03

Conditions studied

  • Primary Biliary Cholangitis (PBC)

Keywords

  • PBC
  • Cognition
  • Fatigue
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects age ≥ 18 years
  • Diagnosis of PBC based on the presence of ≥2 of 3 key disease characteristics
  • fatigue defined for the purposes of this study as a PBC-40 fatigue domain score of ≥29 at screening
  • Clinically significant cognitive symptoms, defined for the purposes of this study as a PBC-40 cognitive domain ≥16 at screening
  • Stable PBC SoC therapy (if any),for at least 3 months prior to randomisation
  • For all women of (WOCBP) a negative pregnancy test at screening and a negative urine dip-stick pregnancy test at baseline, prior to first dose of IMP
  • WOCBP must be willing to use a method with a failure rate of \< 1% and agree to continue use of this method for the duration of the study and thereafter for 1 month after the last dosing of the IMP
  • Females of non-childbearing potential must have documented tubal ligation or hysterectomy; or be
  • Fertile male subjects must be willing to use condom and assure that their female partner will use contraceptive methods with a failure rate of \< 1%
  • Willing and able to give
  • The subject should be judged by the Investigator to be lucid and oriented to person, place, time, and situation when giving the informed consent

Exclusion criteria

Exclusion Criteria:

  • class B or C cirrhosis
  • Clinical evidence of hepatic decompensation (e.g. current or prior HE, ascites, or variceal bleeding)
  • History of hepatocellular carcinoma
  • >1.5 x
  • (GFR) \<35 mL/min/1.73m2
  • Low (HB), i.e. subjects with moderate/severe anaemia
  • Low S-B12 or low P-folate
  • Evidence of biliary obstruction
  • Any positive result on screening for (HIV), or (serum hepatitis B surface antigen positive)
  • Prolonged (>500 ms), or any abnormality in the resting , as judged by the Investigator (at screening)
  • Concomitant disease characterised by chronic fatigue and/or cognitive impairment
  • Clinically significant bowel disease, including obstruction, active inflammatory bowel disease, or malabsorption
  • Clinically significant sleep apnoea
  • An uncontrolled thyroid disorder
  • Subjects with a history of or currently active immune disorders (i.e. uncontrolled) other that PBC (including disease) and/or diseases requiring drugs
  • Clinical diagnosis of autoimmune hepatitis overlap
  • The presence, as judged by the Investigator, of clinically significant concomitant illness which would jeopardise safe participation in the study and /or the interpretation of study findings
  • Regular use of prescribed or over the counter (OTC) medications known to cause fatigue or cognitive dysfunction
  • Use of prohibited medications within 14 days prior to randomisation
  • Anticipated change in PBC medication and/or significant medical or surgical intervention within the duration of the study
  • Regular (more than 1 week per month) alcohol consumption in excess of 14 units per week
  • Administration of another new chemical entity or has participated in any other clinical study that included drug treatment with the last administration within 3 months prior to administration of IMP in this study
  • Females who are pregnant, nursing or actively trying to conceive a child
  • Expected inability to swallow the required number of IMP capsules at the applicable dose level
  • History of severe allergy/ or on-going allergy/hypersensitivity, as judged by the Investigator
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    Part B: Treatment arm 1 (golexanolone 40 mg)

    40 mg golexanolone BID

    Drug: golexanolone

  • Experimental
    Part B: Treatment arm 2 (golexanolone 80 mg)

    80 mg golexanolone BID

    Drug: golexanolone

  • Placebo comparator
    Placebo

    Part B: Placebo BID

    Drug: Placebo

  • Experimental
    Part A: Golexanolone

    40 mg golexanolone BID

    Drug: golexanolone

  • Placebo comparator
    Part A: Placebo

    Placebo BID

    Drug: Placebo

Interventions

  • Druggolexanolone

    soft gelatin capsules, oral dosage twice per day for up to 28 days

  • Druggolexanolone

    soft gelatin capsules, oral dosage twice a day for up to 28 days

  • DrugPlacebo

    soft gelatin capsules, oral dosage twice a day for up to 28 days

  • Druggolexanolone

    soft gelatin capsules, oral dosage twice per day for 5 days

  • DrugPlacebo

    soft gelatin capsules, oral dosage twice per day for 5 days

06

What researchers measure

Primary outcomes

  1. 1. Frequency, intensity, and seriousness of adverse events (AEs) from baseline to Day 28 (part B)

    Frequency, intensity, and seriousness of adverse events (AEs) from baseline to Day 28

    Time frame: From enrollment to the end of treatment at 28 days

  2. Frequency, intensity, and seriousness of adverse events (AEs) from baseline to Day 5 (part A)

    Frequency, intensity, and seriousness of adverse events (AEs)

    Time frame: From Baseline to Day 5

Secondary outcomes

  1. 1. Change from baseline to Day 28 in PBC-40 scores for each of the domains (cognition, itch, fatigue, social, emotional, and general symptoms) (part B)

    The PBC-40 is a patient-derived, disease specific health-related quality of life measure for PBC. The paper questionnaire consists of 40 questions, each scored on a scale of 1 to 5 (where 1=least impact, 5=greatest impact) grouped into six domains (cognition, itch, fatigue, social, emotional, and general symptoms). For each domain, scoring involves summing individual question response scores, range of 6-30. Higher scores indicate a poorer quality of life

    Time frame: From baseline to Day 28

  2. 2. Change from baseline to Day 28 in EQ-5D-3L tool (part B)

    The EQ-5D tool is a standardised measure of health status developed to provide a simple, generic measure of health for clinical and economic appraisal.

    Time frame: From baseline to Day 28

  3. 3. Change from baseline to Day 28 in daytime sleepiness related symptoms using the Epworth Sleepiness Scale (ESS) (part B)

    ESS is a validated self-administered questionnaire for assessment of daytime hypersomnolence. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score (the sum of eight item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'.

    Time frame: From baseline to Day 28

  4. 4. Change from baseline to Day 28 in Portosystemic Hepatic Encephalopathy Score (PHES) total score (part B)

    The PHES is composed of five sub-tests, number connection test-A (NCT-A), number connection test-B (NCT-B), serial dotting test (SDT), line tracing test (LTT) and digit symbol test (DST). PHES assesses motor speed, motor accuracy, concentration, attention, visual perception, visual-spatial orientation, visual construction, and memory.

    Time frame: From baseline to Day 28

  5. 5. Change from baseline to Day 28 in Rey Auditory Verbal Learning test (RAVLT) (part B)

    The RAVLT is a validated word list learning task composed of 15 words that are read to the subject at a rate of one word/second after which the subject is asked to recall as many words as they can. This procedure is repeated five times. The sum of words recalled across these five trials constitutes the immediate recall score.

    Time frame: From baseline to Day 28

  6. 6. Change from baseline to Day 28 in Delis and Kaplan Executive Function System (D-KEFS) Letter and Category fluency subtests (part B)

    The Category Fluency and Letter Fluency tests from the D-KEFS are validated ideational fluency tasks in which the subject is asked to say as many words as possible in 1 minute that adhere to a particular rule.

    Time frame: From baseline to Day 28

  7. 7. To evaluate the Investigator's overall impression of treatment effect by Clinical Global Impression of change, PBC version (CGI-C-PBC) from baseline to Day 28 (part B)

    The clinical global impression (CGI) scale consists of two clinician-rated instruments, CGI-S-PBC and CGI-C-PBC, respectively measuring overall disease severity and change. The CGI-S-PBC entails a 30-45 minute semi-structured interview examining all six clinical domains identified as clinically relevant for patients living with PBC. Domain-specific and global ratings are rendered by trained independent clinical raters who are experts in PBC and have been certified for this purpose to be central raters. All CGI-S-PBC and CGI-C-PBC interviews will be video-recorded and used to support the evaluation made by the raters.

    Time frame: From baseline to Day 28

  8. 8. To assess the exposure of two dose levels of golexanolone in the target population treated for 28 days (part B)

    The lowest plasma concentration before the next dose (Ctrough) will be assessed pre-dose on Days 1, 14, and 28

    Time frame: At Day 1, 14 and 28

07

Study locations

38 sites
  • University Hospital Düsseldorf
    Düsseldorf, 40225, Germany
  • University of Leipzig
    Leipzig, 04103, Germany
  • Hippokration General Hospital of Athens
    Athens, 11527, Greece
  • University Hospital of Patras
    Pátrai, 26504, Greece
  • Facility of CRU Hungary Ltd.
    Kistarcsa, 2143, Hungary
  • Università di Milano-Bicocca, S.C. ASST Grande Ospedale Metropolitano Niguarda, Dipartimento di Medicina e Chirurgia, Epatologia e Gastroenterologia
    Milan, 20162, Italy
  • University of Padova, Department of Surgery, Oncology and Gastroenterology
    Padova, 35128, Italy
  • University Hospital Paolo Giaccone, University of Palermo
    Palermo, 90127, Italy
  • A. Gemelli Polyclinic, Sacro Cuore Catholic University
    Roma, 168, Italy
  • Humanitas University
    Rozzano, 20089, Italy
  • University of Udine
    Udine, 33100, Italy
  • University Medical Center "Zvezdara"
    Belgrade, 11000, Serbia
  • Hospital Universitario Parc Taulí
    Barcelona, 08208, Spain
  • Hospital Clinic Barcelona
    Barcelona, 8036, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Hospital 12th October, Madrid
    Madrid, 28041, Spain
  • Hospital Universitario Virgen De La Victoria
    Málaga, 29010, Spain
  • University Hospital Complex of Pontevedra & IIS Galicia South, Pontevedra
    Pontevedra, 36071, Spain
  • University Hospital Marquez de Valdecilla, Santander
    Santander, 39008, Spain
  • Virgen del Rocio University Hospital
    Seville, 41013, Spain
  • Hospital Universitario y Politécnico La Fe
    Valencia, 46026, Spain
  • Hacettepe University, Fakulty of Medicine, Department of Gastroenterology and Hepatology
    Ankara, 06230, Turkey (Türkiye)
  • 9 Eylul University Research and Application Hospital Department of Gastroenterology
    Balçova, 35340, Turkey (Türkiye)
  • Dicle University Faculty of Medicine Department of Gastroenterology
    Diyarbakır, 21280, Turkey (Türkiye)
  • Ege University Faculty of Medicine, Department of Gastroenterology
    Izmir, 35100, Turkey (Türkiye)
  • Kocaeli University Faculty of Medicine Gastroenterology and Hepatology Department
    Kocaeli, 41100, Turkey (Türkiye)
  • Recep Tayyip Erdoğan University Training and Research Hospital, Department of Gastroenterology
    Rize, 53020, Turkey (Türkiye)
  • Harran Üniversitesi Osmanbey Campus Department of Gastroenterology
    Sanliurfa, 63300, Turkey (Türkiye)
  • Karadeniz Technical University, Farabi Hospital, Department of Gastroenterology
    Trabzon, 61080, Turkey (Türkiye)
  • NIHR Birmingham BRC
    Birmingham, B15 2TT, United Kingdom
  • Glasgow Royal Infirmary
    Glasgow, G4 0SF, United Kingdom
  • Royal Free London NHS Foundation Trust
    London, NW3 2QG, United Kingdom
  • Guy's and St Thomas' Hospital, London
    London, SE1 7EH, United Kingdom
  • Freeman Hospital
    Newcastle, NE7 7DN, United Kingdom
  • Nottingham Digestive Diseases Centre and Biomedical Research Centre Nottingham University Hospitals NHS Trust, Queen's Medical Centre
    Nottingham, NG7 2UH, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust
    Oxford, United Kingdom
  • Dept of Gastroenterology & Hepatology Portsmouth Hospitals University NHS Trust Queen Alexandra Hospital
    Portsmouth, PO6 3LY, United Kingdom
  • Royal Wolverhampton NHS Trust, New Cross Hospital
    Wolverhampton, WV10 0QP, United Kingdom
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Sep 2026, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Dec 26, 2025
StartActual
Apr 14, 2023
Primary completionActual
Sep 9, 2026
CompletionActual
Sep 9, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 16, 2026
Primary completion
Sep 30, 2026→Sep 9, 2026 (actual)
Oct 16, 2026
Study completion
Sep 30, 2026→Sep 9, 2026 (actual)
Oct 16, 2026
Enrollment
84→207 (actual)
Oct 16, 2026
Documents
across 2 updates, Oct 8, 2026 – Oct 16, 2026
Show all 2 updates
  1. Oct 16, 2026
    Active, not recruiting→Completed
    Documents Study protocol ↗ updated
    Primary completion Sep 30, 2026→Sep 9, 2026 (now actual)
    Study completion Sep 30, 2026→Sep 9, 2026 (now actual)
    Enrollment 202 (estimated)→207 (actual)
  2. Oct 8, 2026
    Documents Study protocol ↗ updated
    Enrollment 84→202
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07304843
Lead sponsor
Umecrine Cognition AB
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Apr 14, 2023
Primary completion
Sep 9, 2026
Completion
Sep 9, 2026
Last update
Oct 16, 2026

Study contacts

Pernilla Sandwall
study director · Umecrine Cognition

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion